Madrigal Pharmaceuticals, Inc. (MDGL) Technical Analysis & Indicators
Madrigal Pharmaceuticals, Inc. (MDGL) — Price $400.43 (closing price, November 4, 2026) — Healthcare — Biotechnology — NASDAQ
Latest reported results:
Technical analysis of Madrigal Pharmaceuticals, Inc. (MDGL): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH).